[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:clear-cell-renal-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":216,"states":217},"Clear Cell Renal Cell Carcinoma",34,32,[8,16,23,29,36,42,48,54,61,67,73,79,85,91,97,103,108,114,120,126,132,138,144,150,156,162,168,174,179,185,191,197,203,210],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06661720","Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:17:52.450442Z","2026-07-05T05:32:16.766230Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07564232","Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma",[20],"Phase 1","2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.728124Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07300241","Open-Label Phase 1\u002F2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma",[20],"2026-08-26T02:17:33.807405Z","2026-05-05T02:43:29.668713Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07510334","VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma",[33],"Phase 2","2026-08-26T02:17:05.997056Z","2026-05-05T02:43:29.541232Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06601296","Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer",[33],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:29.468451Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07195682","A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:29.358796Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05536141","A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors",[20],"2026-08-26T02:16:28.221034Z","2026-05-05T02:43:29.352344Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT05287945","Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma",[58],"Phase 1\u002FPhase 2","2026-08-26T02:17:30.145302Z","2026-05-05T02:43:29.048386Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05127824","Autologous Dendritic Cell Vaccine in Kidney Cancer",[33],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.873624Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07123090","A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma",[33],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:28.844644Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05665361","Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)",[58],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:28.471273Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07043608","Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases",[33],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.338318Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05663710","Phase 1b\u002F2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC",[58],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:27.842003Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07187778","Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)",[33],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:27.757489Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07226544","Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer",[33],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:27.754950Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":21,"content_modified":107},"NCT07023432","Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)",[33],"2026-05-05T02:43:27.510172Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07072234","Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.480320Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06940518","Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma",[33],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:27.400434Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT06234605","A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.245677Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05361720","Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study",[33],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:27.089693Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT07223541","Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma",[33],"2026-08-26T02:18:06.247899Z","2026-05-05T02:35:31.915535Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06835972","A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)",[58],"2026-08-26T02:17:42.501124Z","2026-04-29T02:57:57.071659Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06026410","KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",[20],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.472498Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT05433142","Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma",[20],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.325189Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06805825","A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and\u002For Metastatic Solid Tumors Known to Express c-Kit",[20],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.274696Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT07195916","A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",[20],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.041939Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT06447103","An Investigational Scan (89Zr-DFO-GmAb PET\u002FCT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer",[33],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:28.125343Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":172,"content_modified":178},"NCT04989959","[18F]PT2385 PET\u002FCT in Patients With Renal Cell Carcinoma",[20],"2026-05-05T02:43:27.980947Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT07688187","A Study of Theranostic Pair PD-32766D\u002FT in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma",[20],"2026-08-26T02:17:23.750999Z","2026-07-19T19:36:05.151781Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":189,"content_modified":190},"NCT07383441","Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",[12],"2026-08-26T02:16:14.341106Z","2026-06-14T18:39:22.244564Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT00001238","Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders",[],"2026-08-26T02:16:34.792807Z","2026-07-05T18:42:10.720145Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT07062549","Study of 111In-XYIMSR-01 SPECT\u002FCT in Patients With Metastatic Clear Cell Renal Cell",[20],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:28.367319Z",{"nct_id":204,"title":205,"phases":206,"status":207,"updated_at":208,"content_modified":209},"NCT07077083","CAIX PET\u002FCT for Residual or Recurrent Post-ablative ccRCC",[33],"NOT_YET_RECRUITING","2026-08-26T02:15:59.318403Z","2026-05-05T02:43:26.686235Z",{"nct_id":211,"title":212,"phases":213,"status":207,"updated_at":214,"content_modified":215},"NCT07243067","Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer",[],"2026-08-26T02:17:01.714035Z","2026-05-13T02:55:06.680960Z",[],[218,222,226,230,234,238,241,244,248,251,255,258,262,265,268,271,274,277,280,283,287,290,293,296],{"state":219,"count":220,"slug":221},"Texas",18,"texas",{"state":223,"count":224,"slug":225},"California",12,"california",{"state":227,"count":228,"slug":229},"Tennessee",9,"tennessee",{"state":231,"count":232,"slug":233},"New York",8,"new-york",{"state":235,"count":236,"slug":237},"Massachusetts",7,"massachusetts",{"state":239,"count":236,"slug":240},"Michigan","michigan",{"state":242,"count":236,"slug":243},"Ohio","ohio",{"state":245,"count":246,"slug":247},"Maryland",6,"maryland",{"state":249,"count":246,"slug":250},"Minnesota","minnesota",{"state":252,"count":253,"slug":254},"Missouri",5,"missouri",{"state":256,"count":253,"slug":257},"Pennsylvania","pennsylvania",{"state":259,"count":260,"slug":261},"Arizona",4,"arizona",{"state":263,"count":260,"slug":264},"Connecticut","connecticut",{"state":266,"count":260,"slug":267},"Florida","florida",{"state":269,"count":260,"slug":270},"Illinois","illinois",{"state":272,"count":260,"slug":273},"Nebraska","nebraska",{"state":275,"count":260,"slug":276},"New Jersey","new-jersey",{"state":278,"count":260,"slug":279},"Oklahoma","oklahoma",{"state":281,"count":260,"slug":282},"Virginia","virginia",{"state":284,"count":285,"slug":286},"Colorado",3,"colorado",{"state":288,"count":285,"slug":289},"Georgia","georgia",{"state":291,"count":285,"slug":292},"Iowa","iowa",{"state":294,"count":285,"slug":295},"Kentucky","kentucky",{"state":297,"count":285,"slug":298},"Oregon","oregon"]